PTPA and cancer: PP2A dysregulation is commonly observed in cancer, typically through one of several mechanisms, including somatic mutations, haploinsufficiency and/or decreased expression of PP2A subunits, and increased expression of endogenous PP2A inhibitors such as CIP2A7–10.